Accelerating the Development of Biomarkers for Drug Safety
Workshop Summary
Seiten
2009
National Academies Press (Verlag)
978-0-309-38170-3 (ISBN)
National Academies Press (Verlag)
978-0-309-38170-3 (ISBN)
- Titel ist leider vergriffen;
keine Neuauflage - Artikel merken
Biomarkers can be defined as indicators of any biologic state, and they are central to the future of medicine. As the cost of developing drugs has risen in recent years, reducing the number of new drugs approved for use, biomarker development may be a way to cut costs, enhance safety, and provide a more focused and rational pathway to drug development.
On October 24, 2008, the IOM's Forum on Drug Discovery, Development, and Translation held "Assessing and Accelerating Development of Biomarkers for Drug Safety," a one-day workshop, summarized in this volume, on the value of biomarkers in helping to determine drug safety during development.
Table of Contents
Front Matter
1 Introduction
2 Overview of Key Issues
3 Cardiac Safety Biomarkers
4 Assessing and Predicting Kidney Safety
5 Biomarkers of Acute Idiosyncratic Hepatocellular Injury in Clinical Trials
6 Future Considerations
Appendix A: Workshop Agenda
Appendix B: Speaker Biographies
On October 24, 2008, the IOM's Forum on Drug Discovery, Development, and Translation held "Assessing and Accelerating Development of Biomarkers for Drug Safety," a one-day workshop, summarized in this volume, on the value of biomarkers in helping to determine drug safety during development.
Table of Contents
Front Matter
1 Introduction
2 Overview of Key Issues
3 Cardiac Safety Biomarkers
4 Assessing and Predicting Kidney Safety
5 Biomarkers of Acute Idiosyncratic Hepatocellular Injury in Clinical Trials
6 Future Considerations
Appendix A: Workshop Agenda
Appendix B: Speaker Biographies
1 Front Matter; 2 1 Introduction; 3 2 Overview of Key Issues; 4 3 Cardiac Safety Biomarkers; 5 4 Assessing and Predicting Kidney Safety; 6 5 Biomarkers of Acute Idiosyncratic Hepatocellular Injury in Clinical Trials; 7 6 Future Considerations; 8 Appendix A: Workshop Agenda; 9 Appendix B: Speaker Biographies
| Erscheint lt. Verlag | 20.7.2009 |
|---|---|
| Verlagsort | Washington |
| Sprache | englisch |
| Maße | 152 x 229 mm |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie |
| Studium ► 2. Studienabschnitt (Klinik) ► Anamnese / Körperliche Untersuchung | |
| ISBN-10 | 0-309-38170-3 / 0309381703 |
| ISBN-13 | 978-0-309-38170-3 / 9780309381703 |
| Zustand | Neuware |
| Informationen gemäß Produktsicherheitsverordnung (GPSR) | |
| Haben Sie eine Frage zum Produkt? |
Mehr entdecken
aus dem Bereich
aus dem Bereich
Buch | Softcover (2024)
Urban & Fischer in Elsevier (Verlag)
CHF 78,40
aus Klinik und Praxis
Buch | Softcover (2023)
Urban & Fischer (Verlag)
CHF 58,75
Neurographie, Myographie, Evozierte Potenziale und EEG
Buch | Softcover (2024)
Urban & Fischer in Elsevier (Verlag)
CHF 79,95